Bench to bedside targeting of FLT3 in acute leukemia

Keith Pratz, Mark J Levis

Research output: Contribution to journalArticle

Abstract

FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.

Original languageEnglish (US)
Pages (from-to)781-789
Number of pages9
JournalCurrent Drug Targets
Volume11
Issue number7
DOIs
StatePublished - 2010

Fingerprint

Protein-Tyrosine Kinases
Leukemia
Chemotherapy
Off-Label Use
Combination Drug Therapy
Acute Myeloid Leukemia
Labels
Recurrence
Drug Therapy
Mutation
Molecules
Research
Pharmaceutical Preparations

Keywords

  • Acute myeloid leukemia
  • Flt3
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Bench to bedside targeting of FLT3 in acute leukemia. / Pratz, Keith; Levis, Mark J.

In: Current Drug Targets, Vol. 11, No. 7, 2010, p. 781-789.

Research output: Contribution to journalArticle

Pratz, Keith ; Levis, Mark J. / Bench to bedside targeting of FLT3 in acute leukemia. In: Current Drug Targets. 2010 ; Vol. 11, No. 7. pp. 781-789.
@article{0f1012aff7f8475da8f72c4c5b2e91d9,
title = "Bench to bedside targeting of FLT3 in acute leukemia",
abstract = "FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30{\%} of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.",
keywords = "Acute myeloid leukemia, Flt3, Tyrosine kinase inhibitors",
author = "Keith Pratz and Levis, {Mark J}",
year = "2010",
doi = "10.2174/138945010791320782",
language = "English (US)",
volume = "11",
pages = "781--789",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Bench to bedside targeting of FLT3 in acute leukemia

AU - Pratz, Keith

AU - Levis, Mark J

PY - 2010

Y1 - 2010

N2 - FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.

AB - FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several molecules in clinical development inhibit FLT3, but thus far clinical responses have been limited. Correlative studies from monotherapy trials have established that responses require sustained, effective FLT3 inhibition in vivo. Studies combining FLT3 inhibitors with chemotherapy have demonstrated increased remission rates to date but have yet to produce a survival advantage. Currently the only approved FLT3 inhibitor available for off-label use is sorafenib, which clearly has clinical activity but does not commonly lead to a complete response. Several FLT3 inhibitors are currently being tested as single agents and in combination with chemotherapy, and it seems likely that a clinically useful drug will eventually emerge.

KW - Acute myeloid leukemia

KW - Flt3

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=77954750384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954750384&partnerID=8YFLogxK

U2 - 10.2174/138945010791320782

DO - 10.2174/138945010791320782

M3 - Article

C2 - 20370649

AN - SCOPUS:77954750384

VL - 11

SP - 781

EP - 789

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 7

ER -